Risks and limits of APOE Check

The APOE check analyzes ε2, ε3, and ε4 variants linked to Alzheimer's and cardiovascular risk. Evidence for APOE ε4 and late-onset Alzheimer's is human-strong (large GWAS, meta-analyses). However, key limits apply: a single test does not diagnose disease – many ε4 carriers never develop Alzheimer's, and ε4-negative individuals can still get it. Lifestyle factors (exercise, diet, sleep) and other genetic/epigenetic modifiers play major roles. Risks include psychological distress (anxiety, stigma) and false reassurance for ε4-negatives. Medical guidelines do not recommend routine APOE testing for asymptomatic individuals due to lack of proven preventive benefit. Testing should only be done with genetic counseling and cautious interpretation. MyBody-X emphasizes this is an informational test, not a medical diagnosis. Evidence is strong, but clinical utility for individuals remains limited.